United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $544.30, for a total value of $4,517,690.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $24,587,119.60. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

United Therapeutics Stock Down 1.5%

UTHR stock traded down $8.39 during midday trading on Friday, hitting $533.12. The company’s stock had a trading volume of 654,280 shares, compared to its average volume of 992,596. United Therapeutics Corporation has a 52-week low of $409.07 and a 52-week high of $609.35. The firm has a 50-day simple moving average of $513.64 and a 200-day simple moving average of $540.40. The firm has a market capitalization of $22.87 billion, a P/E ratio of 19.07, a PEG ratio of 3.87 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $6.41 earnings per share. On average, sell-side analysts expect that United Therapeutics Corporation will post 26.40 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Several hedge funds have recently made changes to their positions in the company. New England Research & Management Inc. increased its stake in shares of United Therapeutics by 110.1% during the third quarter. New England Research & Management Inc. now owns 3,530 shares of the biotechnology company’s stock worth $1,913,000 after acquiring an additional 1,850 shares during the period. TD Waterhouse Canada Inc. raised its holdings in United Therapeutics by 6.0% during the third quarter. TD Waterhouse Canada Inc. now owns 1,302 shares of the biotechnology company’s stock worth $745,000 after purchasing an additional 74 shares in the last quarter. Pension & Wealth Management Advisors Inc. acquired a new stake in United Therapeutics in the third quarter valued at about $108,000. Davidson Capital Management Inc. lifted its position in United Therapeutics by 2.7% in the third quarter. Davidson Capital Management Inc. now owns 11,252 shares of the biotechnology company’s stock valued at $6,097,000 after purchasing an additional 297 shares during the period. Finally, Brindle & Bay Financial Advisors LLC acquired a new stake in United Therapeutics in the third quarter valued at about $234,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research analyst reports. The Goldman Sachs Group reaffirmed a “sell” rating and set a $368.00 price target on shares of United Therapeutics in a research report on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Jefferies Financial Group reiterated a “buy” rating and set a $728.00 target price on shares of United Therapeutics in a research note on Wednesday. Finally, Royal Bank Of Canada raised their price target on United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $642.69.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics settled six patent and antitrust disputes with Liquidia, reducing legal uncertainty around Liquidia’s YUTREPIA inhaled treprostinil treatment. The agreement limits YUTREPIA’s label, including excluding pulmonary hypertension associated with interstitial lung disease, which could help protect UTHR’s competitive position. United Therapeutics Settles Litigation And Resets Pulmonary Hypertension Competition
• Positive Sentiment: The settlement is expected to provide United Therapeutics with approximately $380.7 million in payments, while giving investors greater visibility into the competitive landscape for treprostinil therapies. United Therapeutics Stock May Be Undervalued Following the Litigation Settlement
• Positive Sentiment: Traders purchased 12,089 UTHR call options, roughly 220% above average daily volume. The activity signals increased bullish speculation, although options flow does not guarantee sustained buying in the shares.
• Positive Sentiment: Analyst sentiment remains generally favorable. Jefferies reaffirmed a Buy rating with a $728 target, and the broader analyst consensus remains “Moderate Buy,” with targets above recent trading levels.
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.13 million, reducing her holdings by 2.84%. She still retains a substantial position, so the sale may reflect personal financial planning rather than a change in the company’s outlook. United Therapeutics CEO Stock Sale SEC Filing
• Negative Sentiment: EVP Paul Mahon sold 8,300 shares for approximately $4.52 million, cutting his direct stake by 15.52%. The second executive sale disclosed within two days may weigh on sentiment, even though insider transactions alone do not establish a deterioration in fundamentals. United Therapeutics EVP Stock Sale SEC Filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.